Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Next Previous
X
Search
Trial Profile

A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA

    • Most Recent Events

    • 23 Nov 2022 Results of the integrated safety (n=1083) profile of evobrutinib using pooled data from (NCT02975349, NCT03233230, NCT02975336) multiple sclerosis (MS), rheumatoid arthritis and systemic lupus erythematosus trials, published in the Journal of Neurology, Neurosurgery and Psychiatry.
    • 26 Apr 2022 Results of a pooled analysis (NCT02975349, NCT03233230 and NCT02975336) assessed the safety profile, including class-related treatment-emergent adverse events presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 15 Oct 2021 Results of a pooled analysis of data from 3 phase II studies (NCT02975349, NCT03233230 and NCT02975336) assessing the Safety profile characterisation of evobrutinib in over 1000 patients presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top